Physician profile
Mark H Smith
NPI 1104036458
$3,996.46
in general payments reported to CMS, 2019-2025
12 companies · $36.18 in 2025
The $36.18 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,577 · 2020: $273 · 2021: $309 · 2023: $34.01 · 2024: $1,768 · 2025: $36.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,110 · Food and Beverage: $719 · Gift: $8.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,109.71 |
| Food and Beverage | $719.27 |
| Gift | $8.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,123.81 | 2019-2024 | |
| Medical Device Business Services, INC. | $768.49 | 2019 | |
| Ethicon US, LLC | $250.39 | 2019 | |
| Sanara Medtech INC. | $240.16 | 2020-2021 | |
| Tetraphase Pharmaceuticals, INC. | $225.00 | 2019-2020 | |
| Davol INC. | $169.58 | 2019-2024 | Phasix Mesh |
| Integra Lifesciences Corporation | $119.20 | 2019 | |
| Medtronic, INC. | $36.18 | 2025 | Endo Gia Ultra, Signia |
| Kerecis Limited | $17.84 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Smith+Nephew, INC. | $16.17 | 2023 | Pico 7, Renasys Go V2 Home |
| Medela LLC | $15.30 | 2024 | Invia Motion Endure |
| Coopersurgical, INC. | $14.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.